Hyperbaric oxygen therapy for Alzheimer’s dementia with positron emission tomography imaging: A case report

Harch, Paul G.; Fogarty, Edward F

doi:10.4103/2045-9912.248271

Cited by 29 publications

(32 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, an immediate increase in CBF due to a reduction in the number of stalled capillaries led to rapid improvement in the performance of 5XFAD mice in spatial and working memory tasks [ 15 ]. Recent human studies have shown that HBOT can improve cognitive functions of mild cognitive impairment (MCI), AD and vascular dementia patients [ 37 – 39 , 73 ] and ameliorate the reduced brain metabolism of MCI and AD patients [ 37 , 39 ]. Here, we showed that HBOT increases CBF and improves cognitive function in elderly individuals suffering from significant memory loss, as well as increasing CBF, alleviating cerebral hypoxia and improving behavioral deficits in 5XFAD mice.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Hyperbaric oxygen therapy alleviates vascular dysfunction and amyloid burden in an Alzheimer’s disease mouse model and in elderly patients

Shapira

Gdalyahu

Gottfried

et al. 2021

Aging

View full text Add to dashboard Cite

Vascular dysfunction is entwined with aging and in the pathogenesis of Alzheimer’s disease (AD) and contributes to reduced cerebral blood flow (CBF) and consequently, hypoxia. Hyperbaric oxygen therapy (HBOT) is in clinical use for a wide range of medical conditions. In the current study, we exposed 5XFAD mice, a well-studied AD model that presents impaired cognitive abilities, to HBOT and then investigated the therapeutical effects using two-photon live animal imaging, behavioral tasks, and biochemical and histological analysis. HBOT increased arteriolar luminal diameter and elevated CBF, thus contributing to reduced hypoxia. Furthermore, HBOT reduced amyloid burden by reducing the volume of pre-existing plaques and attenuating the formation of new ones. This was associated with changes in amyloid precursor protein processing, elevated degradation and clearance of Aß protein and improved behavior of 5XFAD mice. Hence, our findings are consistent with the effects of HBOT being mediated partially through a persistent structural change in blood vessels that reduces brain hypoxia. Motivated by these findings, we exposed elderly patients with significant memory loss at baseline to HBOT and observed an increase in CBF and improvement in cognitive performances. This study demonstrates HBOT efficacy in hypoxia-related neurological conditions, particularly in AD and aging.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Recently, it was shown that HBOT improved cognitive performance in animal models of Alzheimer’s disease [ 17 , 36 ], and improved the metabolic status and cognitive scores of AD and amnestic mild cognitive impairment patients [ 37 – 39 ]. However, it is not known if HBOT mitigates cerebrovascular dysfunction in AD.…”

Section: Introductionmentioning

confidence: 99%

Hyperbaric oxygen therapy alleviates vascular dysfunction and amyloid burden in an Alzheimer’s disease mouse model and in elderly patients

Shapira

Gdalyahu

Gottfried

et al. 2021

Aging

View full text Add to dashboard Cite

show abstract

“…The therapies for these diseases are directed to the improvement of oxygen capture through techniques such as hyperbaric chamber and coenzyme Q treatments. 30 31 Thus, the principal strategy underlying hyperbaric oxygen treatment is to increase the oxygen level in tissues. Furthermore, since a small increase in the pO 2 in ischemic areas increases the bactericidal activity of leukocytes, Cytoreg, as a therapeutic ionic agent, could play an important role in the regulation of these immune cells.…”

Section: Discussionmentioning

confidence: 99%

Effect of an ionic antineoplastic agent Cytoreg on blood chemistry in a Wistar rat model

et al. 2022

View full text Add to dashboard Cite

Cytoreg is an ionic therapeutic agent comprising a mixture of hydrochloric, sulfuric, phosphoric, hydrofluoric, oxalic, and citric acids. In diluted form, it has demonstrated efficacy against human cancers in vitro and in vivo . Although Cytoreg is well tolerated in mice, rats, rabbits, and dogs by oral and intravenous administration, its mechanism of action is not documented. The acidic nature of Cytoreg could potentially disrupt the pH and levels of ions and dissolved gases in the blood. Here, we report the effects of the intravenous administration of Cytoreg on the arterial pH, oxygen and carbon dioxide pressures, and bicarbonate, sodium, potassium, and chloride concentrations. Our results demonstrate that Cytoreg does not disturb the normal blood pH, ion levels, or carbon dioxide content, but increases oxygen levels in rats. These data are consistent with the excellent tolerability of intravenous Cytoreg observed in rabbits, and dogs. The study was approved by the Bioethics Committee of the University of the Andes, Venezuela (CEBIOULA) (approval No. 125) on November 3, 2019.

show abstract

“…Growing evidence suggests that HBOT can induce the neuroplasticity and improve the cognitive function in patients suffering from neurocognitive impairment due to stroke and brain injuries. [ 45 , 46 ] Moreover, HBOT cannot only improve cognitive functions and ameliorate the brain glucose metabolism in AD and amnestic MCI (aMCI) patients [ 4 , 47 ] but also induce significant senolytic effects including significantly increasing telomere length and clearance of senescent cells in the aging individuals. [ 48 ]…”

Section: Recent Progress In the Research Of Admentioning

confidence: 99%

Current Alzheimer disease research highlights: evidence for novel risk factors

Brenowitz

Xiang

McEvoy

et al. 2021

Chinese Medical Journal

View full text Add to dashboard Cite

Alzheimer disease (AD) is the most common type of dementia characterized by the progressive cognitive and social decline. Clinical drug targets have heavily focused on the amyloid hypothesis, with amyloid beta (Aβ), and tau proteins as key pathophysiologic markers of AD. However, no effective treatment has been developed so far, which prompts researchers to focus on other aspects of AD beyond Aβ, and tau proteins. Additionally, there is a mounting epidemiologic evidence that various environmental factors influence the development of dementia and that dementia etiology is likely heterogenous. In the past decades, new risk factors or potential etiologies have been widely studied. Here, we review several novel epidemiologic and clinical research developments that focus on sleep, hypoxia, diet, gut microbiota, and hearing impairment and their links to AD published in recent years. At the frontiers of AD research, these findings and updates could be worthy of further attention.

show abstract

Hyperbaric oxygen therapy for Alzheimer’s dementia with positron emission tomography imaging: A case report

Cited by 29 publications

References 48 publications

Hyperbaric oxygen therapy alleviates vascular dysfunction and amyloid burden in an Alzheimer’s disease mouse model and in elderly patients

Hyperbaric oxygen therapy alleviates vascular dysfunction and amyloid burden in an Alzheimer’s disease mouse model and in elderly patients

Effect of an ionic antineoplastic agent Cytoreg on blood chemistry in a Wistar rat model

Current Alzheimer disease research highlights: evidence for novel risk factors

Contact Info

Product

Resources

About